Supporting evidence
Empagliflozin × HbA1c
- Authoritative support
- 8
- Available studies
- 8
- Unavailable support
- 0
Available supporting studies
Study 1 · Included
Adding medications improves blood sugar control in diabetes patients.
Rct
- Comparison
- Participants received empagliflozin as a third line therapy in addition to ongoing metformin and dpp 4 inhibitors. · Participants received pioglitazone as a third line therapy in addition to ongoing metformin and dpp 4 inhibitors. · Participants received glimepiride as a third line therapy in addition to ongoing metformin and dpp 4 inhibitors.
- Duration / follow-up
- 3900 weeks
Relevant effects
Mean difference
0.78
Mean difference
0.89
Mean difference
0.93
Study 2 · Included
Combination therapy improves liver health in type 2 diabetes
Rct
- Comparison
- Participants received a combination of PIO and EMPA daily for 24 weeks. · Participants received PIO alone daily for 24 weeks. · Participants received EMPA alone daily for 24 weeks.
- Duration / follow-up
- 24 weeks
Relevant effects
Absolute change
1.3 · 0.003
Absolute change
1.3 · 0.003
Absolute change
1.3 · 0.003
Study 3 · Included
Empagliflozin improves glycemic control in type 2 diabetes patients
Rct
- Comparison
- Patients receiving empagliflozin 10 mg as add on treatment. · Patients receiving empagliflozin 25 mg as add on treatment. · Patients receiving placebo as add on treatment.
- Duration / follow-up
- 52 weeks
Relevant effects
Mean difference
0.7 · 0.0001
Mean difference
0.8 · 0.0001
Study 4 · Included
Empagliflozin improves heart function in type 2 diabetes patients
Rct
- Comparison
- Patients received empagliflozin 10 mg/day. · Patients received a placebo.
- Duration / follow-up
- 12 weeks
Study 5 · Limited
Empagliflozin improves nighttime glycemia in type 1 diabetes
Rct
- Duration / follow-up
- 8 weeks
Relevant effect
Mean difference
0.41 · 0.0001
Study 6 · Included
Empagliflozin reduces body fluid volume in type 2 diabetes patients
Rct
- Comparison
- Patients received empagliflozin for 12 weeks after initial treatment. · Patients received glimepiride for 12 weeks after initial treatment.
- Duration / follow-up
- 136 weeks
Study 7 · Included
Empagliflozin reduces HbA1c in youth with type 2 diabetes
Rct
- Comparison
- Drug naïve adolescents receiving empagliflozin for 26 weeks. · Drug naïve adolescents receiving linagliptin for 26 weeks. · Drug naïve adolescents receiving placebo for 26 weeks. · Young adults receiving empagliflozin for 24 weeks. · Young adults receiving sitagliptin for 24 weeks. · Young adults receiving placebo for 24 weeks.
- Duration / follow-up
- 884 weeks
Relevant effects
Mean difference
0.35 · 0.017
Mean difference
1.01
Study 8 · Included
Intermittent Fasting Diet Improves Glycemic Control in Type 2 Diabetes
Rct
- Comparison
- Participants received a 16 week intermittent fasting plan consisting of 2 nonconsecutive fasting days and 5 days of habitual intake. · Participants received metformin for 16 weeks. · Participants received empagliflozin for 16 weeks.
- Duration / follow-up
- 16 weeks
Relevant effects
Mean difference
1.9
Mean difference
1.6
Mean difference
1.5